MYC and Familial prostate cancer: Future studies are needed to validate these findings in larger cohorts, assess the viability of targeting ArA metabolism therapeutically, and determine whether ArA-based imaging agents demonstrate specific uptake in MYC-high/KMT2A-low prostate cancers.